Discovery Life Sciences and Partner to Advance Liquid Biopsy Development and Immunotherapy Research


SAN DIEGO–, the healthcare industry’s leading marketplace for outsourced research, and Discovery Life Sciences™ (Discovery), a global leader in biospecimen solutions, genomic, cell and immunohistochemistry (IHC) services, have partnered to offer researchers online access to Illumina’s TruSight™ Oncology 500 (TSO500) technology. The TSO500 technology was recently added to HudsonAlpha Discovery™, Discovery’s highly regarded sequencing and bioinformatics laboratory.

“HudsonAlpha Discovery’s TSO500 platform combined with Discovery Life Sciences’ comprehensive biospecimen solutions, which are also available through, will accelerate immuno-oncology and liquid biopsy biomarker studies through delivery of actionable NGS data across patient-matched tumor and plasma biospecimens,” stated Kevin Lustig, PhD, CEO and founder of “This cutting-edge technology is now available to all users under one pre-established legal agreement, accelerating preclinical research and enabling faster science.”

Illumina’s TSO500 solid Tumor (FFPE) and ctDNA technology enables genomic characterization across a broad range of tumor types through the identification of somatic variants from DNA and RNA, including critical immuno-oncology SNV, InDel, CNV and fusion biomarkers, as well as microsatellite instability (MSI) and tumor mutational burden (TMB).

“Our services are optimized for efficiency to enable rapid delivery of the valuable NGS data that only TSO500 provides across matched FFPE and plasma samples at any scale,” stated Dr. Shawn Levy, PhD, Chief Scientific Officer at Discovery Life Sciences. “By making these new services available on, we will advance biomarker programs and allow researchers to more quickly develop and validate new immunotherapeutics, liquid biopsy diagnostics and companion diagnostics.”